Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 130

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 130
---
 to establish and maintain collaborations on favorable terms, if at all;                  |
| ● | our                                                                                              
 efforts to enhance operational systems and our ability to attract, hire and retain qualified     
 personnel, including personnel to support the development of our drug candidate;                 |
| ● | the                                                                                              
 costs associated with being a public company; and                                                |
| ● | the                                                                                              
 cost associated with commercializing our drug candidate, if it receives marketing approval.      |

If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties rights to develop or commercialize our drug candidate that we would prefer to retain.

See “ Risk Factors” for additional risks associated with our capital requirements.

| 73 |

Cash Flows for the Nine months ended September 30, 2025 and 2024

The following table shows a summary of our cash flows for the nine months ended September 30, 2025 and 2024.

|                                          |     | For the Nine months ended  September 30, 
 2025                                     |            |   |     | 2024 |          |   |
|:-----------------------------------------|:----|:-----------------------------------------|:-----------|:--|:----|:-----|---------:|:--|
| Net cash flows from operating activities |     | $                                        | (3,045,713 | ) |     | $    | (215,225 | ) |
| Net cash flows from investing activities |     |                                          | -          |   |     |      |        - |   |
| Net cash flows from financing activities |     | $                                        | -          |   |     | $    |  187,000 |   |
| Net increase (decrease) in cash          |     | $                                        | (3,045,713 | ) |     | $    |  (28,225 | ) |

Net